What is the most likely diagnosis and recommended diagnostic and management plan for a patient with bilateral renal masses and a pancreatic cyst?

Bilateral Renal Masses with Pancreatic Cyst: Most Likely Diagnosis and Management

The combination of bilateral renal masses and a pancreatic cyst should immediately raise suspicion for Von Hippel-Lindau (VHL) syndrome, and you must obtain dedicated pancreatic MRI/MRCP and contrast-enhanced CT chest/abdomen/pelvis to characterize all lesions, followed by genetic testing for VHL. 1, 2

Most Likely Diagnosis

Von Hippel-Lindau syndrome is the primary diagnosis to consider when encountering this specific constellation of findings. This autosomal dominant disorder causes:

• Bilateral renal cell carcinomas (typically clear cell type)
• Pancreatic cysts and neoplasms (including serous cystadenomas, pancreatic neuroendocrine tumors with clear cell features)
• Multiple organ involvement including CNS hemangioblastomas, pheochromocytomas

The presence of walls and internal septations in the pancreatic mass with gadolinium enhancement particularly suggests VHL syndrome 1. Clear-cell pancreatic endocrine neoplasms in VHL can mimic metastatic renal cell carcinoma cytologically, making accurate diagnosis critical 2.

Diagnostic Workup Algorithm

Immediate Imaging (Priority Order):

1. Pancreatic MRI/MRCP - This is the preferred modality for pancreatic cyst characterization 3

   • More sensitive than CT for identifying mural nodules, internal septations, and communication with pancreatic duct
   • Essential for distinguishing between benign serous cystadenomas and mucinous lesions with malignant potential
   • Avoids repeated radiation exposure needed for lifelong surveillance 3

2. Contrast-enhanced CT chest/abdomen/pelvis - For complete staging 4

   • Characterize renal masses (size, enhancement pattern, local invasion)
   • Detect pulmonary metastases (most accurate for lung lesions)
   • Identify calcifications in pancreatic lesions if present 3
   • Critical caveat: CT chest is strongly recommended except for cT1a renal tumors which have low metastatic risk 4

3. Brain MRI - Screen for CNS hemangioblastomas if VHL suspected

Tissue Diagnosis:

For renal masses:

• Perform percutaneous renal mass biopsy using coaxial core needle technique 4
• Core biopsies have 78-97% diagnostic yield with 98-100% specificity for malignancy
• Coaxial technique minimizes seeding risk 4
• Biopsy avoids unnecessary interventions for benign lesions and guides surveillance decisions

For pancreatic cyst:

• EUS with contrast harmonic enhancement (CH-EUS) is recommended 3
• EUS-FNA should be performed if mural nodules or solid components present
• Cyst fluid analysis for CEA, amylase, and molecular markers (GNAS, KRAS mutations) helps differentiate mucinous from non-mucinous cysts 3
• Important pitfall: Do not biopsy purely cystic pancreatic lesions without solid components - diagnostic yield is poor 4

Genetic Testing:

• VHL gene testing - Essential given the clinical presentation
• Refer to genetics for counseling and family screening

Management Strategy

For Renal Masses:

The 2025 EAU guidelines provide clear direction 4:

• If bilateral RCC confirmed: Nephron-sparing surgery (partial nephrectomy) is critical to preserve renal function
• Active surveillance is an option for small renal masses in VHL given multifocal disease and need for repeated interventions
• Timing of intervention depends on growth kinetics and largest lesion size
• Avoid bilateral nephrectomy - preserve maximum renal function given lifelong disease burden

For Pancreatic Cyst:

Management depends on cyst type 3:

If serous cystadenoma (microcystic adenoma):

• These are benign with no malignant potential 1
• No surgical intervention required unless symptomatic
• Surveillance MRI can be stopped after confirming diagnosis

If mucinous cystic neoplasm (MCN):

• Surgical resection recommended if ≥40mm (grade IB recommendation) 3
• Surgery also indicated for any size if symptomatic or imaging signs of malignancy
• These have malignant potential requiring definitive treatment

If branch duct IPMN:

• Assess for high-risk stigmata (mural nodules >5mm, main duct dilation >10mm, solid component)
• Surgical resection if high-risk features present
• Otherwise, lifelong MRI surveillance 3

If pancreatic neuroendocrine tumor:

• Common in VHL syndrome
• Size-based approach: >2cm typically requires resection
• Clear-cell variant can be confused with metastatic RCC - immunohistochemistry essential 2

Critical Pitfalls to Avoid

1. Do not assume pancreatic lesion is metastatic RCC - VHL patients develop primary pancreatic neoplasms that can have clear-cell features mimicking metastases 2

2. Do not use CT alone for pancreatic surveillance - MRI is superior and avoids cumulative radiation exposure in patients requiring lifelong monitoring 3

3. Do not perform routine brain or bone imaging for localized renal disease unless symptomatic, but DO image brain in suspected VHL 4

4. Do not biopsy Bosniak I/II renal cysts - malignancy rate is very low 4

5. Do not delay genetic testing - VHL diagnosis impacts screening protocols for patient and family members

Surveillance Protocol Once Diagnosed

• Renal imaging: Annual MRI or CT
• Pancreatic imaging: Annual MRI/MRCP (if cyst requires surveillance)
• CNS imaging: Every 2-3 years for hemangioblastomas
• Biochemical screening: Annual for pheochromocytoma
• Ophthalmologic exam: Annual for retinal angiomas

This algorithmic approach prioritizes accurate diagnosis of VHL syndrome, appropriate tissue characterization to guide treatment, and organ-preserving strategies that optimize long-term quality of life in this hereditary cancer syndrome.